Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Moxifloxacin Activates the SOS Response in Mycobacterium tuberculosis in a Dose- and Time-Dependent Manner
Angelo Iacobino, Giovanni Piccaro, Manuela Pardini, et al.
Microorganisms (2021) Vol. 9, Iss. 2, pp. 255-255
Open Access | Times Cited: 18

Showing 18 citing articles:

Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity
Preshendren Govender, Rudolf Müller, Kawaljit Singh, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6903-6925
Open Access | Times Cited: 24
Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease
Jickky Palmae Sarathy, Min Xie, Chui Fann Wong, et al.
ACS Infectious Diseases (2025)
Open Access
Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones
Gregory S. Basarab, Sandeep R. Ghorpade, Liezl Gibhard, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 4
Open Access | Times Cited: 18
Endogenous relapse and exogenous reinfection in recurrent pulmonary tuberculosis: A retrospective study revealed by whole genome sequencing
Wencong He, Yun‐Hong Tan, Zexuan Song, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 10
Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus
Dereje A. Negatu, Andreas Beuchel, Abdeldjalil Madani, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 8
Open Access | Times Cited: 21
Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics
Kirsten E. Knoll, Jeremie Zander Lindeque, Adetomiwa A. Adeniji, et al.
Microorganisms (2021) Vol. 9, Iss. 6, pp. 1158-1158
Open Access | Times Cited: 19
Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
Scott Grossman, Colin W. G. Fishwick, Martin J. McPhillie
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 261-261
Open Access | Times Cited: 6
Dissecting the RecA-(In)dependent Response to Mitomycin C in Mycobacterium tuberculosis Using Transcriptional Profiling and Proteomics Analyses
Anna Brzostek, Przemysław Płociński, Alina Minias, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 1168-1168
Open Access | Times Cited: 14
Microfluidic dose–response platform to track the dynamics of drug response in single mycobacterial cells
Maxime Mistretta, Nicolas Gangneux, Giulia Manina
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics
Kirsten E. Knoll, Jeremie Zander Lindeque, Adetomiwa A. Adeniji, et al.
Antibiotics (2021) Vol. 10, Iss. 6, pp. 693-693
Open Access | Times Cited: 13
Structure–Activity Relationship of Anti-Mycobacterium abscessus Piperidine-4-carboxamides, a New Class of NBTI DNA Gyrase Inhibitors
Andreas Beuchel, Dina Robaa, Dereje A. Negatu, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 3, pp. 417-427
Open Access | Times Cited: 9
Transmission dynamics of Tuberculosis in a high-burden area of China: an 8-year population-based study using whole genome sequencing
Wencong He, Yun‐Hong Tan, Zexuan Song, et al.
International Journal of Infectious Diseases (2024) Vol. 147, pp. 107210-107210
Open Access | Times Cited: 1
Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We Stand
Alessio Lanni, Angelo Iacobino, Lanfranco Fattorini, et al.
(2023)
Open Access | Times Cited: 2
Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We Stand
Alessio Lanni, Angelo Iacobino, Lanfranco Fattorini, et al.
Microorganisms (2023) Vol. 11, Iss. 6, pp. 1511-1511
Open Access | Times Cited: 2
Identification of Rv1133c (MetE) as a marker of Mycobacterium tuberculosis replication and as a highly immunogenic antigen with potential immunodiagnostic power
Angelo Iacobino, Raffaela Teloni, Carmine Mancone, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Navigating the Challenge of Tuberculosis Drug Resistance: Unveiling Intrinsic and Acquired Pathways to Overcome the Threat
Hafiz Muhammad Aslam, Muhammad Umar Sharif, Amna Uroos, et al.
Journal of Advances in Microbiology (2024) Vol. 24, Iss. 6, pp. 12-29
Open Access
Integration of multi-modal measurements identifies critical mechanisms of tuberculosis drug action
William Johnson, A. Paul Alivisatos, Trever C. Smith, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Synergistic effect of repurposed mitomycin C in combination with antibiotics against Aeromonas infection: in vitro and in vivo studies
Cheng-Fa Yeh, Chi‐Chung Chen, Chih‐Cheng Lai, et al.
Journal of Microbiology Immunology and Infection (2024)
Open Access
Dynamics of drug response in single mycobacterial cells by microfluidic dose-response assay
Maxime Mistretta, Nicolas Gangneux, Giulia Manina
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top